Novel <i>LZTR1</i> germline mutation as a mechanism of resistance to osimertinib in <i>EGFR</i>-mutated lung adenocarcinoma: a case report.

ABSTRACT:

Background

Tyrosine kinase inhibitors (TKIs) are now the standard of care first-line therapy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) patients. Despite positive outcomes in most patients, with extended progression-free survival (PFS), a small population of patients respond poorly to these drugs. Complex genetic and non-genetic resistance mechanisms may be the drivers of disease in cancer, but further research is required to identify these mechanisms in the clinic. Germline molecular testing alongside broad-panel somatic next-generation sequencing (NGS) has allowed for detection of resistance mutations in EGFR-mutated NSCLC patients that may be linked with poor response on TKIs.

Case description

Here, we pre

SUBMITTER: Park W 

PROVIDER: S-EPMC11921366 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature